Becton, Dickinson and Company $BDX Holdings Decreased by Checchi Capital Advisers LLC

Checchi Capital Advisers LLC reduced its holdings in Becton, Dickinson and Company (NYSE:BDX) by 20.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,863 shares of the medical instruments supplier’s stock after selling 471 shares during the period. Checchi Capital Advisers LLC’s holdings in Becton, Dickinson and Company were worth $321,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of BDX. Saudi Central Bank purchased a new position in Becton, Dickinson and Company during the first quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company during the 1st quarter valued at $27,000. Alpine Bank Wealth Management acquired a new position in shares of Becton, Dickinson and Company in the first quarter worth $29,000. Cornerstone Planning Group LLC raised its holdings in shares of Becton, Dickinson and Company by 341.4% during the first quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after acquiring an additional 99 shares in the last quarter. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new stake in Becton, Dickinson and Company during the first quarter valued at $31,000. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Insider Activity at Becton, Dickinson and Company

In other news, Director Claire Fraser sold 917 shares of the stock in a transaction that occurred on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total value of $171,937.50. Following the completion of the sale, the director directly owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael David Garrison sold 1,185 shares of the business’s stock in a transaction on Friday, July 18th. The stock was sold at an average price of $180.29, for a total transaction of $213,643.65. Following the transaction, the executive vice president directly owned 4,887 shares in the company, valued at $881,077.23. This trade represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,023 shares of company stock worth $562,036. Company insiders own 0.36% of the company’s stock.

Wall Street Analyst Weigh In

BDX has been the subject of a number of recent research reports. Wells Fargo & Company raised their price target on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a research note on Friday, August 8th. Piper Sandler reaffirmed a “neutral” rating and set a $200.00 price objective (up previously from $185.00) on shares of Becton, Dickinson and Company in a research report on Friday, August 8th. Wall Street Zen upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research note on Saturday, August 9th. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a research note on Monday, September 15th. Finally, Morgan Stanley lifted their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the company an “overweight” rating in a research note on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat.com, Becton, Dickinson and Company presently has an average rating of “Hold” and an average target price of $205.40.

Becton, Dickinson and Company Price Performance

Shares of Becton, Dickinson and Company stock opened at $191.94 on Tuesday. The firm has a fifty day simple moving average of $189.21 and a 200-day simple moving average of $186.79. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. Becton, Dickinson and Company has a 1-year low of $163.33 and a 1-year high of $251.99. The stock has a market capitalization of $55.02 billion, a price-to-earnings ratio of 34.52, a PEG ratio of 1.51 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 EPS for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same quarter last year, the firm posted $3.50 EPS. The business’s quarterly revenue was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Shareholders of record on Monday, September 8th were issued a $1.04 dividend. The ex-dividend date of this dividend was Monday, September 8th. This represents a $4.16 dividend on an annualized basis and a yield of 2.2%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 74.82%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.